Turn Therapeutics Reports Strong Interim Phase 2 Results for GX-03 in Atopic Dermatitis

summarizeSummary

Turn Therapeutics reported strong interim Phase 2 clinical trial results for its lead drug candidate GX-03 in atopic dermatitis, showing high efficacy and a favorable safety profile, leading to trial optimization and planned FDA discussions.

check_boxKey Events

• Positive Interim Phase 2 Results

  GX-03 achieved a 92.6% EASI-50 (50% reduction in eczema severity) in 4 weeks, 70.4% EASI-75 in 4 weeks, and 51.9% EASI-90 (90% reduction) in 8 weeks for subjects with moderate-to-severe atopic dermatitis.

• Favorable Safety and Tolerability

  No treatment-related serious adverse events, tolerability issues, or discontinuations were observed during the interim analysis period.

• Trial Optimization and Regulatory Strategy

  The company is refining enrollment criteria and endpoint selection based on interim findings and is preparing for FDA interactions to discuss the evolving regulatory strategy for GX-03.

• Upcoming Presentation

  Detailed findings from the interim analysis will be presented at the Jefferies Global Healthcare conference on June 4, 2026.

auto_awesomeAnalysis

Turn Therapeutics announced positive interim Phase 2 clinical trial results for its lead candidate, GX-03, in moderate-to-severe atopic dermatitis. The data shows high efficacy rates (92.6% EASI-50, 51.9% EASI-90 by Week 8) and a favorable safety profile, with no serious adverse events. This is a critical development for a clinical-stage biotechnology company, especially given the prior disclosure of substantial doubt about its ability to continue as a going concern in its March 31, 2026 10-K filing. The company is now optimizing the trial and preparing for FDA interactions, which could accelerate the program's path to market and significantly de-risk the company's future.